“Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from Resurface 1 and Resurface 2”, J of Skin, vol. 4, no. 5, p. s39, Sep. 2020, doi: 10.25251/skin.4.supp.39.